NGM282 (Aldafermin)

Aldafermin · NGM Biopharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for NGM282 (Aldafermin), covering 2013-12-31 to 2025-06-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of NGM282 in Patients With Primary Sclerosing Cholangitis [Phase 2]